# Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

> **NCT00968890** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 168 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pandemrix (Influenza vaccine GSK2340272A)
- **BIOLOGICAL:** Fluarix™
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00968890
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-12
- **Primary completion:** 2010-09-23
- **Final completion:** 2010-09-23
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968890, "Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00968890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*